The FAME II trial was suspended after preliminary findings showed using fractional flow reserve technology in PCI for patients with coronary artery disease significantly reduced hospital readmissions and the need for urgent revascularization. The study's safety monitoring board said it would be unethical for St. Jude Medical to continue to randomly assign patients treatment without FFR.

Related Summaries